The EdU assay revealed that either shFAK or FAK inhibitor administration significantly diminished the enhanced proliferative capacity of HNSCC cells driven by TNS4 overexpression (Figure 4A). Here, TNS4 is linked to head and neck squamous cell carcinoma.